Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer

Breast cancer (BC) with expression of the estrogen receptor (ER) and/or progesterone receptor (PR) protein and with overexpression/amplification of the human epidermal growth factor receptor 2 (HER2), termed hormone receptor-positive (HR+)/HER2+ BC, represents ∼10% of all BCs in the United States. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Pegram, Mark, Pietras, Richard, Dang, Chau T., Murthy, Rashmi, Bachelot, Thomas, Janni, Wolfgang, Sharma, Priyanka, Hamilton, Erika, Saura, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422890/
https://www.ncbi.nlm.nih.gov/pubmed/37576607
http://dx.doi.org/10.1177/17588359231187201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422890/
https://www.ncbi.nlm.nih.gov/pubmed/37576607
http://dx.doi.org/10.1177/17588359231187201

Ejemplares similares